Short Report

You have full text access to this OnlineOpen article

Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo

  1. Ludger Grosse-Hovest1,
  2. Wolfgang Wick2,
  3. Rosa Minoia3,
  4. Michael Weller2,
  5. Hans-Georg Rammensee1,
  6. Gottfried Brem4,
  7. Gundram Jung1,†,*

Article first published online: 7 JUL 2005

DOI: 10.1002/ijc.21294

Issue

International Journal of Cancer

International Journal of Cancer

Volume 117, Issue 6, pages 1060–1064, 20 December 2005

Additional Information

How to Cite

Grosse-Hovest, L., Wick, W., Minoia, R., Weller, M., Rammensee, H.-G., Brem, G. and Jung, G. (2005), Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo. Int. J. Cancer, 117: 1060–1064. doi: 10.1002/ijc.21294

Author Information

  1. 1

    Institute for Cell Biology, Department of Immunology, Eberhard Karls University Tübingen, Tübingen, Germany

  2. 2

    Department of Neurology, Eberhard Karls University Tübingen, Tübingen, Germany

  3. 3

    Department of Animal Production, University of Bari, Bari, Italy

  4. 4

    Ludwig Boltzmann Institute for Immuno-, Cyto- and Molecular Genetic Research, University of Veterinary Medicine, Vienna, Austria

  1. †

    Fax: +49-7071-295653.

*Institute for Cell Biology, Department of Immunology, Eberhard Karls University Tübingen, Auf der Morgenstelle 15, Tübingen, 72076, Germany

Publication History

  1. Issue published online: 20 OCT 2005
  2. Article first published online: 7 JUL 2005
  3. Manuscript Accepted: 20 APR 2005
  4. Manuscript Received: 1 FEB 2005

Funded by

  • The Paktis Antibody Services
  • Wilhelm Sander Foundation. Grant Number: 2001.114.1
  • German Ministry for Education and Research. Grant Number: PTJ 0312625

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (202K)

References

  • 1
    Hurwitz AA, Kwon ED, van Elsas A. Costimulatory wars: the tumor menace. Curr Opin Immunol 2000; 12: 589–96.
  • 2
    Kroczek RA, Mages HW, Hutloff A. Emerging paradigms of T-cell co-stimulation. Curr Opin Immunol 2004; 16: 321–7.
  • 3
    Tacke M, Hanke G, Hanke T, Hunig T. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur J Immunol 1997; 27: 239–47.
    Direct Link:
  • 4
    Luhder F, Huang Y, Dennehy KM, Guntermann C, Muller I, Winkler E, Kerkau T, Ikemizu S, Davis SJ, Hanke T, Hunig T. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 2003; 197: 955–66.
  • 5
    Grosse-Hovest L, Hartlapp I, Marwan W, Brem G, Rammensee HG, Jung G. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur J Immunol 2003; 33: 1334–40.
    Direct Link:
  • 6
    Grosse-Hovest L, Muller S, Minoia R, Wolf E, Zakhartchenko V, Wenigerkind H, Lassnig C, Besenfelder U, Muller M, Lytton SD, Jung G, Brem G. Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing. Proc Natl Acad Sci USA 2004; 101: 6858–63.
  • 7
    Galea-Lauri J, Darling D, Gan SU, Krivochtchapov L, Kuiper M, Gaken J, Souberbielle B, Farzaneh F. Expression of a variant of CD28 on a subpopulation of human NK cells: implications for B7-mediated stimulation of NK cells. J Immunol 1999; 163: 62–70.
  • 8
    Wilson JL, Charo J, Martin-Fontecha A, Dellabona P, Casorati G, Chambers BJ, Kiessling R, Bejarano MT, Ljunggren HG. NK cell triggering by the human costimulatory molecules CD80 and CD86. J Immunol 1999; 163: 4207–12.
  • 9
    Tibben JG, Boerman OC, Massuger LF, Schijf CP, Claessens RA, Corstens FH. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab′)2 in ovarian carcinoma patients. Int J Cancer 1996; 66: 477–83.
    Direct Link:
  • 10
    De Jonge J, Heirman C, De Veerman M, Van Meirvenne S, Moser M, Leo O, Thielemans K. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 × anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model. J Immunol 1998; 161: 1454–61.
  • 11
    Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, der Lieth CW, Matys ER, Little M. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 1999; 293: 41–56.
  • 12
    Dreier T, Baeuerle PA, Fichtner I, Grun M, Schlereth B, Lorenczewski G, Kufer P, Lutterbuse R, Riethmuller G, Gjorstrup P, Bargou RC. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 2003; 170: 4397–402.
View Full Article (HTML) Get PDF (202K)